Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...
ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...
SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations for treatment.
NEW ORLEANS -- Treatment with the PCSK9 inhibitor alirocumab (Praluent) safely lowered LDL cholesterol versus placebo in transplant patients already on rosuvastatin, but did not reduce the development ...
Although some of the barriers that have kept cholesterol-lowering PCSK9 inhibitors out of reach for many patients in the United States have eased a bit in recent years, a new analysis suggests that ...
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...
WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...
Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable ...
Please provide your email address to receive an email when new articles are posted on . Large LDL reductions were maintained long term with lerodalcibep, a monthly PCSK9 inhibitor. Results were ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipid-lowering drugs, were associated with a 22% lower risk for nonmelanoma skin cancer (NMSC) in patients with atherosclerotic ...
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback